{"nctId":"NCT00666718","briefTitle":"A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients","startDateStruct":{"date":"2008-04"},"conditions":["Diabetes Mellitus, Type 2"],"count":374,"armGroups":[{"label":"Glargine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin Glargine","Drug: Insulin Lispro"]},{"label":"ILPS","type":"EXPERIMENTAL","interventionNames":["Drug: Insulin Lispro Protamine Suspension (ILPS)","Drug: Insulin Lispro"]}],"interventions":[{"name":"Insulin Glargine","otherNames":[]},{"name":"Insulin Lispro Protamine Suspension (ILPS)","otherNames":["LY275585"]},{"name":"Insulin Lispro","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diabetes Mellitus, Type 2\n* Have been receiving metformin and at least one other oral antihyperglycemic medication (sulfonylurea or thiazolidinedione) with insulin for at least 3 months prior to Visit 1 (Screening)\n* Hemoglobin A1C (HbA1c) greater than or equal to 7.5% and less than or equal to 11.0%\n* Body Mass Index (BMI) greater than or equal to 25 and less than or equal to 45 kg/m\\^2\n* Capable and willing to follow the protocol\n* Give written consent\n\nExclusion Criteria:\n\n* Are taking any glucose-lowering agents (other than those listed in the inclusion criteria above)\n* Have a history of severe hypoglycemia in the past 6 months\n* Are pregnant or may become pregnant\n* Women who are breastfeeding\n* Have significant cardiac disease\n* Have significant renal or liver disease\n* Undergoing therapy for a malignancy\n* Contraindications to the study medications\n* Have an irregular sleep/wake cycle\n* Have a serious disease or any condition considered by the investigator to be exclusionary","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c) to Week 24","description":"Least Squares Mean (LSMean) values reported in the table were controlled for treatment, country, and baseline HbA1c value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"0.08"},{"groupId":"OG001","value":"-1.18","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c at Week 12 and Week 24","description":"LSMean values presented were controlled for treatment, country, baseline HbA1C value and week.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.99","spread":null},{"groupId":"OG001","value":"-0.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.29","spread":null},{"groupId":"OG001","value":"-1.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c Less Than 7.0% and Less Than or Equal to 6.5% at Endpoint","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"7-point Self-monitored Blood Glucose Profiles (SMBG) at Endpoint","description":"LSMean values presented were controlled for treatment, country, and baseline HbA1C value. SMBG at morning pre-meal, morning postprandial, midday pre-meal, midday postprandial, evening pre-meal, evening postprandial, 0300 hours. Postprandial glucose is measured 2 hours after the start of the meal.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.26","spread":"0.22"},{"groupId":"OG001","value":"8.63","spread":"0.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.93","spread":"0.25"},{"groupId":"OG001","value":"9.19","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.19","spread":"0.23"},{"groupId":"OG001","value":"7.90","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.11","spread":"0.25"},{"groupId":"OG001","value":"9.58","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.80","spread":"0.24"},{"groupId":"OG001","value":"8.75","spread":"0.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.27","spread":"0.24"},{"groupId":"OG001","value":"9.73","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.16","spread":"0.22"},{"groupId":"OG001","value":"8.30","spread":"0.35"}]}]}]},{"type":"SECONDARY","title":"Glycemic Variability at Endpoint","description":"LSMeans were controlled for treatment and country grouping (Mediterranean, rest of Europe). Glycemic variability was assessed as the standard deviations of 4 fasting SMBG samples, 4 post-breakfast measurements, 4 post-lunch measurements, 4 post-evening meal measurements.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"0.10"},{"groupId":"OG001","value":"0.95","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.56","spread":"0.17"},{"groupId":"OG001","value":"1.64","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.61","spread":"0.15"},{"groupId":"OG001","value":"1.51","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"0.17"},{"groupId":"OG001","value":"1.40","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Rate Of All Self-reported Hypoglycemic Episodes","description":"Rate of self-reported hypoglycemic episodes, all, non-nocturnal,and nocturnal, severe, documented ≤3.9 mmol/L and ≤3.0 mmol/L. Rate=episodes/30 days/patient/. Episode=any time a patient has a symptom associated with hypoglycemia or blood glucose level of ≤70 mg/dL,even if not associated with symptoms.Overall=any time post-randomization in the study period. Nocturnal=Episode between bedtime and waking. Non-Nocturnal=Episode between waking and bedtime.Severe:episode in which patient requires assistance,and has glucose \\<50 mg/dL or prompt recovery after oral carbohydrate, glucagon, or IV glucose.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":"0.21"},{"groupId":"OG001","value":"0.84","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.05"},{"groupId":"OG001","value":"0.15","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":"0.20"},{"groupId":"OG001","value":"0.71","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.013"},{"groupId":"OG001","value":"0","spread":"0.029"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"0.15"},{"groupId":"OG001","value":"0.49","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.04"},{"groupId":"OG001","value":"0.12","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Self-Reported Hypoglycemic Episodes","description":"Episode=any time a patient feels that he/she is experiencing a sign or symptom associated with hypoglycemia or has a blood glucose level of ≤70 mg/dL, even if not associated with signs,symptoms, or treatment. Overall=any time post-randomization visits in the study period. Nocturnal=Episode that occurs between bedtime and waking. Non-Nocturnal=Episode occurring between waking and bedtime. Severe=episode with symptoms of neuroglycopenia in which patient requires assistance,and has blood glucose value \\<50 mg/dL or prompt recovery after oral carbohydrate, glucagon, or intravenous glucose.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null},{"groupId":"OG001","value":"56.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":null},{"groupId":"OG001","value":"25.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","spread":null},{"groupId":"OG001","value":"54.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AE)","description":"A listing of adverse events is located in the Reported Adverse Event module.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline to Week 24","description":"LSMean values presented were controlled for treatment, country, and baseline HbA1C value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":"0.27"},{"groupId":"OG001","value":"1.03","spread":"0.30"}]}]}]},{"type":"SECONDARY","title":"Total Daily Insulin Dose at Endpoint","description":"LSMean values presented were controlled for treatment, country, and baseline HbA1C value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.05","spread":"3.15"},{"groupId":"OG001","value":"80.23","spread":"4.31"}]}]}]},{"type":"SECONDARY","title":"Number of Injections of Insulin at Week 24","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":187},"commonTop":["Nasopharyngitis","Headache","Viral infection","Diarrhoea","Cough"]}}}